Coronary Artery / Peripheral Artery Disease
Coronary Artery / Peripheral Artery Disease
CKJX839B12302 Enrolling

Research Trial for Cardiovascular Disease (3-6 Years)

Age: 40 Years

Qualified individuals must be male or female, aged 40 or older with established cardiovascular (CV) disease, defined as any of the following:

– Previous myocardial infarction

– Previous ischemic stroke

– Symptomatic peripheral arterial disease (PAD)

At the Screening Visit, participants must also be on a stable and well-tolerated lipid-lowering regimen.

Participants will receive an investigational medication (active study drug) or placebo, via injection. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last about 3-6 years depending on when participants enter the study. The number of visits to the study centre will vary (4 to 7 times in the first year, and then twice a year thereafter).

Official Title

A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) ID



Novartis Pharmaceuticals

Study Description

  • Brief Summary:

    Novartis Pharmaceuticals

  • Condition or Disease:

    Atherosclerotic Cardiovascular Disease

  • Intervention/Treatment:

    Drug: Inclisiran sodium 300 mg Drug: Placebo
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    40 Years and older (Adult,Older Adult)

  • Sexes Eligible for Study:


Inclusion Criteria:

Fasting LDL-C ≥ 70 mg/dL at randomization visit
Stable (greater than or equal to 4 weeks) and well-tolerated lipid-lowering regimen (including e.g. with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin greater than or equal to 40 mg QD or rosuvastatin greater than or equal to 20 mg QD

Established CV disease defined as ANY of the following three conditions

Spontaneous Myocardial infarction ≥ 4 weeks from screening visit
History of ischemic stroke occurred ≥ 4 weeks prior to the Screening visit
Symptomatic peripheral arterial disease (PAD) evidenced by either intermittent claudication with ankle brachial index (ABI) < 0.85, prior peripheral arterial revascularization procedure, or, amputation due to atherosclerotic disease.

Exclusion Criteria:

Acute coronary syndrome, stroke, peripheral arterial revascularization procedure or amputation due to atherosclerotic disease < 4 weeks before screening visit
Treatment with PCSK9 inhibitors (e.g. evolocumab, alirocumab) within 90 days or planned use post first study visit
Planned or expected cardiac, cerebrovascular or peripheral artery surgery or coronary re-vascularization within the 6 months after the first study visit
Heart failure NYHA class III or IV
Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver
Previous exposure to inclisiran or any other non-mAb PCSK9-targeted therapy, either as an investigational or marketed drug within 2 years
Severe concomitant non-CV disease that is expected to reduce life expectancy to less than 5 years
History of malignancy that required surgery radiation therapy and/or systemic therapy during the 3 years prior to the first study visit
Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.

Participating Locations


Participating Experts

Dr. Michael Hartleib, MSc, MD, FRCPC


You May Also Be Interested In

Similar Trials

No Similar Trials Found

Learn More About

Coronary Artery / Peripheral Artery Disease

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials

Filter By Keyword

Trial Name, Intervention and or Treatment, Trial Number, Reference Number, Study Info, Sponsors Phase, and Status.